Drug Trial Radar · NCT05113251
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
927
Actual
Start
Oct 25, 2021
Primary completion
Mar 12, 2025
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Nov 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.
Conditions
- Breast Neoplasms
- Breast Cancer
- HER2-positive Early Breast Cancer
Interventions
Trastuzumab DeruxtecanDrug
administered by intravenous infusion
PaclitaxelDrug
administered by intravenous infusion
TrastuzumabDrug
administered by intravenous infusion
PertuzumabDrug
administered by intravenous infusion
DoxorubicinDrug
administered by intravenous infusion
cyclophosphamideDrug
administered by intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Pathologic Complete Response (pCR).Time frame: Through to definitive surgery or discontinuation/withdrawal from study, up to a maximum of approximately 40 months from randomization to primary pCR DCO (12MAR2025)
Locations
145 sites in 18 countries. Site status is shown where the registry gives one.
Research Site
Springdale, Arkansas
Research Site
Beverly Hills, California
Research Site
Glendale, California
Research Site
Los Alamitos, California
Research Site
Orange, California
Research Site
New Haven, Connecticut
Research Site
Fort Wayne, Indiana
Research Site
Lexington, Kentucky
Research Site
Louisville, Kentucky
Research Site
Shreveport, Louisiana
Research Site
Minneapolis, Minnesota
Research Site
Las Vegas, Nevada
Research Site
East Brunswick, New Jersey
Research Site
Summit, New Jersey
Research Site
Commack, New York
Research Site
Durham, North Carolina
Research Site
Greenville, South Carolina
Research Site
Germantown, Tennessee
Research Site
Nashville, Tennessee
Research Site
Fort Worth, Texas
Research Site
Ogden, Utah
Research Site
Tacoma, Washington
Research Site
Goiânia, Brazil
Research Site
Ijuí, Brazil
Research Site
Natal, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Panagyurishte, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Montreal, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Sherbrooke, Quebec, Canada
Research Site
Beijing, China
Research Site
Changsha, China
Research Site
Changsha, China
Showing 40 of 145 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.